DYSTROGEN THERAPEUTICS
Dystrogen Therapeutics is a clinical-stage regenerative medicine company focusing on rare diseases. The company was founded based on the pioneering work of Prof. Maria Siemionow, a world-renowned scientist and surgeon who led the team that performed the first near-total face transplantation in the United States. Professor Siemionow’s research focused on the creation of chimeric cells. This led to the development of Dystrophin Expressing Chimeric (DEC) cell therapy. DECs work by combining a ma... lfunctioning cell of the Duchenne patient with a normal, working cell from a healthy donor. This novel chimeric cell is composed of both the donor and the recipient structures and interacts with the surroundings like a normal cell. This offers a unique advantage and allows the patient's body and immune system to accept the chimeric cell without rejection. In such a way, we have created dystrophin producing cells that can engraft the patient's muscles (such as heart, diaphragm, skeletal muscles) and increase their dystrophin levels. Increased dystrophin levels have been shown to correlate with improved functional outcomes. This technology was developed at the University of Illinois in Chicago. Dystrogen Therapeutics is currently focused on the development of a cell-based therapy platform. The company is testing dystrophin expressing chimeric (DEC) cells, cell-based therapy for the treatment of Duchenne muscular dystrophy.
DYSTROGEN THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics Wellness
Founded:
2017-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.dystrogen.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.09 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins Sitelinks Search Box
Similar Organizations
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.dystrogen.com
- Host name: 169.41.180.107.host.secureserver.net
- IP address: 107.180.41.169
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260

More informations about "Dystrogen Therapeutics"
Home - Dystrogen Therapeutics Corporation
Engineered for Patients Dystrogen Therapeutics Is a clinical stage chimeric cell therapy company focusing on rare diseases. The company is currently testing Dystrophic Expressing Chimeric …See details»
Dystrogen Therapeutics - Crunchbase Company Profile …
Dystrogen Therapeutics is a clinical-stage regenerative medicine company focusing on rare diseases. The company was founded based on the …See details»
Overview - Dystrogen Therapeutics Corporation
Overview Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company was founded …See details»
Dystrogen Therapeutics (Chicago, IL)
Dystrogen Therapeutics (Chicago, IL) Leadership Team Source: Company filings and FactSet. Market data as of 10/05/2021. (1) Also serves on the Board of Directors. • Clinical-stage …See details»
Dystrogen Therapeutics - The Org
Dystrogen Therapeutics is a clinical-stage regenerative medicine company focusing on rare diseases. The company is currently testing DEC therapy for Duchenne Muscular Dystrophy. …See details»
Dystrogen Therapeutics - Funding, Financials, Valuation & Investors
Dystrogen Therapeutics has raised a total of . obfuscated. obfuscated. in funding over 1 round. This was a Venture - Series Unknown round raised on Aug 5, 2019. ... How much funding has …See details»
Dystrogen Therapeutics - Org chart - The Org
Explore Dystrogen Therapeutics' organizational chart. Discover current team members including executives, board members, and advisors.See details»
Dystrogen Therapeutics - Craft
Dystrogen Therapeutics is a clinical-stage regenerative medicine company focusing on rare genetic diseases. It is engaged in the testing of dystrophin expressing chimeric (DEC) therapy …See details»
Dystrogen Therapeutics - VentureRadar
Dystrogen Therapeutics VentureRadar profile. Find out more about Dystrogen Therapeutics, Stem Cells and Cellular Therapy.See details»
Dystrogen Therapeutics - Company Profile - Tracxn
Feb 24, 2025 Dystrogen Therapeutics - Chimeric cell therapy for Duchenne Muscular Dystrophy. Raised a total funding of $1.09M over 1 round from 1 investor. Founded by Kris Siemionow, …See details»
Press - Dystrogen Therapeutics Corporation
Corporate Profile Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company focus on treating …See details»
Dystrogen Therapeutics S.A. – Company Profile - Starfinder
Dystrogen Therapeutics S.A., a Poznan, Poland based company, was established in February 2018 to develop therapies for patients with rare disorders. The company’s first candidate is a …See details»
Kris Siemionow - Co-Founder & CEO at Dystrogen Therapeutics
Co-Founder & CEO at Dystrogen Therapeutics. Show contact. ... Siemionow is co-founder of Global Spine Outreach a non-for profit organization whose mission is to “save children with …See details»
Dystrogen Therapeutics - Overview, News & Competitors
Dystrogen Therapeutics. Business Services · Illinois, United States · <25 Employees. Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized …See details»
Dystrogen Therapeutics - Contacts, Employees, Board Members, …
Dystrogen Therapeutics is a clinical-stage regenerative medicine company focusing on rare diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log …See details»
Dystrogen Therapeutics - PitchBook
Dystrogen Therapeutics General Information Description. Developer of novel chimeric cell therapy designed to treat patients with Sarcopenia. The company's platform uses a proprietary …See details»
Executive Team - Dystrogene Gene Therapie
PhD, Co-Founder and Board Member. Dr. Lewicki is a cognitive scientist, an entrepreneur, and investor. He was a professor of cognitive psychology at the University of Tulsa from 1984 …See details»
Pipeline - Dystrogen Therapeutics Corporation
Dystrogen Therapeutics is focused on the development of Cell Therapy Platform. Program Indications Phase; DT-DEC01. DMD. DT-200. Neuro-Degenerative. DT-201. Sarcopenia. DT …See details»
Dystrogen Gene Therapies - Overview, News & Similar ... - ZoomInfo
View Dystrogen Gene Therapies (www.dystrogene.com) location in Illinois, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Press - Dystrogene Gene Therapie
Apr 5, 2019 Date Localization Conference About; 20-22 June 2022: Krakow, PL: EUROBIOTECH - 8th Central European Congress of Life Sciences: Scientist from Dystrogene …See details»